Freedom of information (FOI) releases from MHRA

This is a disclosure log of Medicines and Healthcare products Regulatory Agency's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters

  • Keywords filters

  • Year filters

  • Month filters

951 disclosures

  1. FOI - Social Media Management Tool

    The information that we require is as follows:- 1) Do you use a social media management platform? 2) If so, what tools do you use? 3) What is your annual spend on a Social media management tool? 4) What dates does your contract with your current supplier end ( month & year) ? 5)Do you use a social listening / media monitoring platform? 6) If so, what tools do you use? 7) What is your annual spend on a social listening / media monitoring tool? 8) What dates does your contract with your current supplier end ( month & year) 9) Who is the senior person responsible for managing these contracts?

    Published: 2 July 2025

  2. Contact details of MHRA Licensing staff

    We'd like to request the names and professional contact details of those who oversee the MHRA licensing drafting & publication processes.

    Published: 23 June 2025

  3. Unlicensed medicines in UK

    Can you please share the list of medicines which are unlicensed here in UK. Also, please share database where we can check if a certain medicine in licensed or unlicensed.

    Published: 23 June 2025

  4. FOI Request - COVID Vaccine Trial Data Redactions

    Please provide any correspondence or internal memos between the MHRA and Pfizer or Moderna relating to the redaction of clinical trial data submitted for UK vaccine authorisation. If this request exceeds the cost limit, please prioritise correspondence from 2020-2022. Please provide the information in digital format.

    Published: 23 June 2025

  5. FOI2025/00422 request acknowledgment

    I would like to amend the request to: Would you please supply the name of the Expert Geneticist or Geneticists, who analysed multiple malformations in table D (page 36) and table E (page 54) in Annex 24 of the Expert Working Group

    Published: 23 June 2025

  6. Information about Sipavibart/Kavigale

    AstraZeneca have confirmed that Sipavibart/Kavigale is under assessment by the MHRA. Please can you provide details to: - how far along the assessment process the department is - how many emails has MHRA received regarding sipavibart - when that process is due to conclude

    Published: 23 June 2025

  7. ADR data - MMR vaccine

    Please can you provide the vaccine injuries and deaths caused by the MMR vaccines since it was introduced.

    Published: 23 June 2025

  8. MHRA Yellow Card - Interactive Drug Analysis Profiles

    I am writing to inquire about the iDAP (Interactive Drug Analysis Profiles) that you provide. I am interested in understanding the internal data preprocessing and cleaning methods and pathways employed before the adverse drug reaction (ADR) data is made available through iDAP. If possible, I would greatly appreciate any information you can provide regarding this process.

    Published: 23 June 2025

  9. MAAs for Hydroxocobalamin solution for injection

    Please can you advise if there are any pending Marketing Authorisation Applications for Hydroxocobalamin solution for injection? Please can you advise the submission date of any such MAAs, and the strength of Hydroxocobalamin solution for injection in each case?

    Published: 23 June 2025

  10. Disclosure log request: GLP1s

    Please could you confirm: * How many UK spontaneous reports with GLP-1RAs, indicated for weight management, that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? * How many UK spontaneous reports with GLP-1RAs, linked to use for treating type 2 diabetes, that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? * How many UK spontaneous reports with GLP-1RAs, linked to with the treatment of weight management and diabetes in combination , that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? * How many UK spontaneous reports with GLP-1RAs, linked to with any treatment apart from type 2 diabetes or weight management, that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? And please could you : * Break down the total number of UK spontaneous reports with GLP-1RAs (linked to any treatment use) that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today) by the name of the GLP-1 agonist involved in the report.

    Published: 23 June 2025